Circulating levels of nitric oxide in fertile women in relation to the menstrual cycle

Cicinelli, Ettore; Ignarro, Louis J.; Lograno, M.D.; Galantino, Pietro; Balzano, Gabriella; Schönauer, Luca Maria

doi:10.1016/s0015-0282(16)58706-8

Cited by 73 publications

(48 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In later studies by the same group, treatment of postmenopausal women with both oestrogen and progesterone induced a slight elevation in plasma NO 3 +NO 2 levels, while oestrogen alone increased these levels significantly (Rosselli et al 1995, Imthurn et al 1997. Plasma NO 3 +NO 2 levels are lower in the secretory phase of the menstrual cycle than at the mid cycle and it has been suggested that this may be due to increased progesterone production during the secretory phase (Cicinelli et al 1996, Kawano et al 1996. These observations correspond well with the finding in the present study that concurrent administration of oestrogen and progestagen to ovariectomized rats partly prevented the decrease in plasma NO 3 +NO 2 levels.…”

Section: Discussionmentioning

confidence: 97%

“…Previous studies in premenopausal women have shown that plasma NO 3 +NO 2 levels increase during follicular development, peak at mid cycle and are correlated with plasma 17 -oestradiol levels (Rosselli et al 1994, Cicinelli et al 1996, Kawano et al 1996. In addition, peak expiratory NO concentrations were found to be significantly higher at mid cycle than during menstruation (Kharitonov et al 1994).…”

Section: Discussionmentioning

confidence: 97%

“…Treatment with the NO donor nitroglycerine prevented OVX-induced bone loss and administration of -NAME completely blocked the preventive effect of oestrogen on OVXinduced bone loss (Wimalawansa et al 1996). Nitrate+ nitrite (NO 3 +NO 2 ) plasma levels, which reflect endogenous NO production (Hibbs et al 1992, Shultz & Raij 1992, have been found to correlate positively with serum 17 -oestradiol levels (Rosselli et al 1994, Ramsay et al 1995, Cicinelli et al 1996, Kawano et al 1996, Imthurn et al 1997. On the other hand, progesterone may have a down-regulating effect on NO 3 +NO 2 plasma levels in the presence of oestrogen (Rosselli et al 1994, Cicinelli et al 1996, Kawano et al 1996, Imthurn et al 1997.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Plasma nitrate+nitrite levels are regulated by ovarian steroids but do not correlate with trabecular bone mineral density in rats

Bezooijen

Que²,

Ederveen³

et al. 1998

Journal of Endocrinology

View full text Add to dashboard Cite

Nitric oxide (NO) is a mediator of bone metabolism and its production is under the control of gender hormones in several cell types or tissues. Changes in endogenous NO production, measured as plasma nitrate+nitrite levels, may therefore contribute to ovariectomy (OVX)-induced bone loss. We studied plasma nitrate+nitrite levels and trabecular bone mineral density (TBMD) 4 weeks after shamoperation or OVX in rats receiving various hormonal treatments. OVX decreased plasma nitrate+nitrite levels significantly and this was accompanied by a significant decrease in TBMD. Treatment with oral ethinyl oestradiol (EE) and subcutaneous 17 -oestradiol dose-dependently prevented the decrease in plasma nitrate+nitrite levels after OVX, but treatment with oral 17 -oestradiol did not. Oestrogen treatment, 17 -oestradiol (s.c. or orally) or EE (orally), prevented the OVX-induced decrease in TBMD. Treatment of sham-operated rats with the anti-oestrogen ICI164,384 induced a significant decrease in TBMD that corresponded to 54% of the decrease observed after OVX, but did not affect plasma nitrate+nitrite levels. Treatment of ovariectomized rats with Org 2058, a pure progestagen, did not prevent bone loss, but prevented the decrease in plasma nitrate+nitrite levels dose-dependently. Treatment with tibolone, a synthetic steroid with combined weak oestrogenic, progestagenic, and androgenic properties, or with progestagen in combination with EE completely prevented bone loss after OVX. These treatments, however, only partly prevented the OVX-induced decrease in plasma nitrate+nitrite levels. In conclusion, OVX decreased both TBMD and plasma nitrate+nitrite levels. Although plasma nitrate+nitrite levels were under the control of both oestrogen and progesterone, TBMD was affected by oestrogen only. Decreased systemic production of NO is, therefore, not involved in OVX-induced bone loss in rats.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 97%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Plasma nitrate+nitrite levels are regulated by ovarian steroids but do not correlate with trabecular bone mineral density in rats

Bezooijen

Que²,

Ederveen³

et al. 1998

Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…During all visits, side effects of the paroxetine and severity of MD symptoms were systematically assessed. Experimental design in the collection of the NOx blood samples varied slightly between male and female subjects, due to the need to control for menstrual cycle, as different phases of the menstrual cycle can effect circulating levels of NOx (Cicinelli et al, 1996). For both MD and HC males, venous blood samples were taken at baseline, after 2 weeks, 6 and 8 weeks of treatment, and between 8 and 12 days after discontinuation of paroxetine.…”

Section: Subjects Design and General Proceduresmentioning

confidence: 99%

“…For both MD and HC males, venous blood samples were taken at baseline, after 2 weeks, 6 and 8 weeks of treatment, and between 8 and 12 days after discontinuation of paroxetine. For both MD and HC females, venous blood samples were taken at baseline, after 8 weeks of treatment, and again after discontinuation for one full menstrual cycle with all visits scheduled prior to midcycle, as NOx levels peak during this time of the menstrual cycle (Cicinelli et al, 1996). Owing to the large amount of blood required (approximately 40 ml) and the time-intensive nature of the NOS assay, for both males and females, venous blood samples for the analysis of platelet activity were collected only at baseline and after 8 weeks of treatment.…”

Section: Subjects Design and General Proceduresmentioning

confidence: 99%

Alteration of Decreased Plasma NO Metabolites and Platelet NO Synthase Activity by Paroxetine in Depressed Patients

Chrapko

Jurasz

Radomski

et al. 2005

Neuropsychopharmacol

View full text Add to dashboard Cite

Although major depression (MD) and cardiovascular disease (CVD) have been conclusively linked in the literature, the mechanism associating MD and CVD is yet undetermined. The purpose of this paper is to further investigate a potential mechanism involving nitric oxide (NO) and to examine the effect of the selective serotonin reuptake inhibitor paroxetine on NO production by both platelets and the endothelium. In total, 17 subjects with MD and 12 healthy controls (HCs) with no known history of cardiovascular illness completed the study. Paroxetine was administered to both the MD patients and HCs over an 8-week period, and then medication was discontinued. Blood samples were taken at various times throughout paroxetine treatment and after discontinuation. Plasma NO metabolite (NOx) levels were measured by a chemiluminescence method. Platelet endothelial NO synthase (eNOS) activity was examined through the conversion of L-[14 C]arginine to L-[ 14 C]citrulline. Data were analyzed using t-tests and a linear mixed effects model. Baseline levels of both plasma NOx and platelet NOS activity were significantly lower in subjects with MD compared to HCs. Throughout paroxetine treatment, plasma NOx levels increased in both HCs and MD patients. However, platelet eNOS activity decreased in HCs, while no statistically significant change was evidenced in MD patients. These data suggest that, in MD patients, decreased peripheral production of NO, a potential contributor to increased cardiovascular risk, is modified by administration of the antidepressant paroxetine.

show abstract

The Role of Nitric Oxide as a Candidate Molecule for Gene Therapy in Sports Injuries

Rodeo¹,

Izawa²

2000

Gene Therapy and Tissue Engineering in Orthopaedic and Sports Medicine

View full text Add to dashboard Cite

Circulating levels of nitric oxide in fertile women in relation to the menstrual cycle

Cited by 73 publications

References 6 publications

Plasma nitrate+nitrite levels are regulated by ovarian steroids but do not correlate with trabecular bone mineral density in rats

Plasma nitrate+nitrite levels are regulated by ovarian steroids but do not correlate with trabecular bone mineral density in rats

Alteration of Decreased Plasma NO Metabolites and Platelet NO Synthase Activity by Paroxetine in Depressed Patients

The Role of Nitric Oxide as a Candidate Molecule for Gene Therapy in Sports Injuries

Contact Info

Product

Resources

About